Israeli-founded AI biotech Immunai launches drug-discovery collaboration with Boehringer Ingelheim
The collaboration will use Immunai’s single-cell AI platform to identify T-cell targets in cancer and autoimmune diseases
Assessment
An Israeli-founded AI biotech firm is partnering with a major pharmaceutical player to apply its single-cell technology to drug discovery. The focus on T-cell targets for both cancer and autoimmune conditions suggests a dual therapeutic ambition. This deal signals deepening industry interest in AI-driven immunology platforms, and the actual targets identified will be the key metric to watch.